Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions

Cancer Lett. 2014 Jan 1;342(1):60-9. doi: 10.1016/j.canlet.2013.08.031. Epub 2013 Aug 24.

Abstract

Non-alcoholic steatohepatitis (NASH), which involves hepatic inflammation and fibrosis, is associated with liver carcinogenesis. The activation of the renin-angiotensin system (RAS), which plays a key role in blood pressure regulation, promotes hepatic fibrogenesis. In this study, we investigated the effects of (-)-epigallocatechin-3-gallate (EGCG), a major component of green tea catechins, on the development of glutathione S-transferase placental form (GST-P)-positive (GST-P(+)) foci, a hepatic preneoplastic lesion, in SHRSP.Z-Lepr(fa)/IzmDmcr (SHRSP-ZF) obese and hypertensive rats. Male 7-week-old SHRSP-ZF rats and control non-obese and normotensive WKY rats were fed a high fat diet and received intraperitoneal injections of carbon tetrachloride twice a week for 8weeks. The rats were also provided tap water containing 0.1% EGCG during the experiment. SHRSP-ZF rats presented with obesity, insulin resistance, dyslipidemia, an imbalance of adipokines in the serum, and hepatic steatosis. The development of GST-P(+) foci and liver fibrosis was markedly accelerated in SHRSP-ZF rats compared to that in control rats. Additionally, in SHRSP-ZF rats, RAS was activated and inflammation and oxidative stress were induced. Administration of EGCG, however, inhibited the development of hepatic premalignant lesions by improving liver fibrosis, inhibiting RAS activation, and attenuating inflammation and oxidative stress in SHRSP-ZF rats. In conclusion, obese and hypertensive SHRSP-ZF rats treated with a high fat diet and carbon tetrachloride displayed the histopathological and pathophysiological characteristics of NASH and developed GST-P(+) foci hepatic premalignant lesions, suggesting the model might be useful for the evaluation of NASH-related liver tumorigenesis. EGCG might also be able to prevent NASH-related liver fibrosis and tumorigenesis.

Keywords: EGCG; Hypertension; Liver fibrosis; Liver tumorigenesis; Obesity.

MeSH terms

  • Angiotensin II / blood
  • Animals
  • Anticarcinogenic Agents / pharmacology
  • Anticarcinogenic Agents / therapeutic use*
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Catechin / therapeutic use
  • Fatty Liver / blood
  • Fatty Liver / drug therapy*
  • Fatty Liver / etiology
  • Gene Expression
  • Hypertension / complications*
  • Interleukin-6 / blood
  • Interleukin-6 / genetics
  • Lipid Peroxidation
  • Liver / drug effects
  • Liver / enzymology
  • Liver / pathology
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology
  • Liver Neoplasms / prevention & control*
  • Male
  • Non-alcoholic Fatty Liver Disease
  • Obesity / complications*
  • Oxidative Stress
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / metabolism
  • Precancerous Conditions / blood
  • Precancerous Conditions / drug therapy*
  • Precancerous Conditions / etiology
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / metabolism
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Anticarcinogenic Agents
  • Interleukin-6
  • Receptor, Angiotensin, Type 1
  • Tumor Necrosis Factor-alpha
  • Angiotensin II
  • Catechin
  • epigallocatechin gallate
  • Peptidyl-Dipeptidase A